Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.55
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Wressle boosts Europa Oil, Egdon and Union Jack

Thu, 16th Dec 2021 10:56

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Shield Therapeutics PLC, up 27% at 37.00 pence, 12-month range 27.01p-66.00p. The Newcastle, England-based pharmaceutical company says patient access for its Accrufer iron deficiency product rises. Shield secures payer coverage with "several large pharmacy benefit managers" in US. This boosts Accrufer access to roughly 40 million patients.

----------

Europa Oil & Gas Holdings PLC, up 15% at 1.24 pence, 12-month range 1.00p-2.20p. Rises on production update from Wressle hydrocarbon development in North Lincolnshire. Wressle has produced at an average of 666 barrels of oil per day over last seven day period. In early 2022, testing will be completed to see "full potential of the well". Europa holds a 30% stake in Wressle. Egdon Resources PLC also owns 30% and Union Jack Oil PLC 40%. Egdon shares are up 11% and Union Jack up 8.4%.

----------

Ceres Power, up 8.1% at 1,005.00 pence, 12-month range 820.50p-1,626.00p. Credit Suisse starts coverage of the stock with an Outperform rating and 1,450p price target.

----------

AIM - LOSERS

----------

boohoo Group PLC, down 16% at 115.56 p, 12-month range 110.00p-378.90p. Retailer lowers sales and margins guidance due to Omicron uncertainty and as product return rates hit net sales. For the financial year ending February 28, boohoo now expects net sales growth in the 12% to 14% range, cut from previous guidance of a rise of 20% to 25%. In three months to November 30, net sale rise 10% annually to GBP506.2 million from GBP460.7 million. On a two-year basis, net sales are 53% higher. Shares fall to a roughly five-year low.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
19 Sep 2018 08:36

Shield Therapeutics irons losses, agrees commercialisation deal

(Sharecast News) - Iron deficiency treatment specialist Shield Therapeutics narrowed losses as revenues grew in the first half of that saw a series of positive developments.

Read more
13 Sep 2018 11:51

Shield Therapeutics Completes Recruitment For Feraccru Trial

LONDON (Alliance News) - Shield Therapeutics PLC said on Thursday it has completed recruitment of patients for the AEGIS-H2H Phase 3b study of oral Feraccru in subjects suffering from inflammatory

Read more
26 Jul 2018 13:05

Shield Therapeutics Appoints Hans-Peter Hasler To Board

LONDON (Alliance News) - Shield Therapeutics PLC, a commercial stage pharmaceutical company, said Thursday that it has appointed Hans-Peter Hasler as non-executive director with immediate is the a

Read more
20 Jun 2018 16:09

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 21 JuneHSS Hire GroupFriday 22 JuneCambian Fifteen Communications Shipping 25

Read more
14 Jun 2018 13:48

Shield Therapeutics Reports Positive Results From Feraccru Study

LONDON (Alliance News) - Pharmaceutical company Shield Therapeutics PLC said Thursday it has had positive top-line results from its paediatric phase I pharmacokinetics study of its ferric iron is

Read more
12 Jan 2017 09:04

Diurnal Hires Outgoing Mereo BioPharma Finance Chief Bungay

Read more
6 Jan 2017 08:12

Shield Therapeutics sees 'encouraging' demand for oral iron product in England, Germany

(ShareCast News) - AIM-listed pharmaceutical Shield Therapeutics saw "encouraging" demand for its oral iron product in the England and Germany. The company said is seeing "very encouraging signals of demand" after only six months since the commercial launch of Feraccru, which treats of iron deficien

Read more
14 Jun 2016 09:17

Shield Therapeutics Reports Widened Pretax Loss In Maiden 2015 Results

Read more
7 Jun 2016 15:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
26 Feb 2016 09:17

Shield Therapeutics Starts Trading, Gets European Feraccru Approval (ALLIPO)

Read more
12 Feb 2016 11:50

Shield Therapeutics Raises GBP32.5 Million In Delayed AIM IPO (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.